

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>colucci daniel</u> (Last) (First) (Middle) C/O BIOSCRIP, INC. 100 CLEARBROOK ROAD (Street) ELMSFORD NY 10523 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BioScrip, Inc. [BIOS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Vice President, PBM Services
	3. Date of Earliest Transaction (Month/Day/Year) <u>08/29/2013</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, \$.0001 Par Value	08/29/2013		M		9,758	A	\$2.73	12,338	D	
Common Stock, \$.0001 Par Value	08/29/2013		S		9,758	D	\$12.4719 ⁽¹⁾	2,580	D	
Common Stock, \$.0001 Par Value	08/30/2013		M		8,742	A	\$2.73	11,322	D	
Common Stock, \$.0001 Par Value	08/30/2013		S		8,742	D	\$12.3151 ⁽²⁾	2,580	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Employee Stock Option	\$2.73	08/29/2013		M		9,758		04/28/2010 ⁽³⁾	04/28/2019	Common Stock, \$.0001 Par Value	9,758	\$0	8,742	D	
Employee Stock Option	\$2.73	08/30/2013		M		8,742		04/28/2010 ⁽³⁾	04/28/2019	Common Stock, \$.0001 Par Value	8,742	\$0	0	D	
Employee Stock Option	\$6.65							06/16/2011 ⁽³⁾	06/16/2020	Common Stock, \$.0001 Par Value	5,500		5,500	D	
Employee Stock Option	\$4.42							04/26/2012 ⁽⁴⁾	04/26/2021	Common Stock, \$.0001 Par Value	20,000		20,000	D	
Stock Option (Right to Buy)	\$11.04							03/08/2014 ⁽⁴⁾	03/08/2023	Common Stock, Par Value \$0.0001 Per Share	50,000		50,000	D	

Explanation of Responses:

- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$12.45 to \$12.53, inclusive. The reporting person undertakes to provide BioScrip, Inc., any security holder of BioScrip, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$12.30 to \$12.36, inclusive. The reporting person undertakes to provide BioScrip, Inc., any security holder of BioScrip, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- Fully Vested.

4. Vests and becomes exercisable in three equal annual installments commencing on the first anniversary of the date of grant.

/s/ Daniel Colucci

09/03/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.